CANS EXAM | 2026/2027 | 150 VERIFIED QUESTIONS &
CORRECT ANSWERS WITH RATIONALES |CERTIFIED AESTHETIC
NURSE SPECIALIST LATEST UPDATE | PSNCB EXAM PREP
GRADED A+
DESCRIPTION
This comprehensive 150-question practice examination is designed for registered
nurses preparing for the Certified Aesthetic Nurse Specialist (CANS) credential
for the 2026/2027 cycle. Aligned with the official test blueprint, this resource
covers all three Clinical Practice Areas: Aesthetic Injectables (55%),
Laser/Light/Energy-Based Therapies (30%), and Clinical Skin Care (15%). Each
item includes the correct answer and a detailed clinical rationale. Topics
include neurotoxins, dermal fillers, sclerotherapy, nonablative and ablative
laser treatments, chemical peels, topical products, patient assessment, informed
consent, complication management, and ethical considerations. Perfect for
self-assessment, study groups, and final exam readiness.
TABLE OF CONTENTS
Section I Aesthetic Injectables – Neurotoxins ........................ 1–25
Section II Aesthetic Injectables – Dermal Fillers ..................... 26–50
Section III Aesthetic Injectables – Sclerotherapy ...................... 51–55
Section IV Laser, Light & Energy-Based Therapies – Nonablative ........ 56–85
Section V Laser, Light & Energy-Based Therapies – Ablative & Other ... 86–100
Section VI Clinical Skin Care – Topical Products & Devices ............ 101–120
Section VII Clinical Skin Care – Chemical Peels & Exfoliation .......... 121–130
Section VIII Patient Assessment, Consultation & Ethics ................. 131–150
SECTION I: AESTHETIC INJECTABLES – NEUROTOXINS (1-25)
1. What is the primary role of a Certified Aesthetic Nurse Specialist (CANS)?
A. Perform surgical procedures independently
B. Provide non-surgical aesthetic treatments and patient care
C. Manage hospital administration
D. Conduct academic research
Answer: B
Rationale: The CANS credential specifically validates expertise in non-surgical
1
,aesthetic interventions. Surgical procedures require physician training, and
administration or research are not the primary clinical focus of this certification.
2. What is the minimum experience required for CANS certification eligibility?
A. 1 year and 500 hours
B. 2 years and 1,000 hours of aesthetic nursing practice
C. 3 years and 1,500 hours
D. No experience required
Answer: B
Rationale: Eligibility requires substantial clinical exposure to ensure the nurse
has developed sufficient judgment and technical skill. The 2-year/1,000-hour
threshold reflects the need for hands-on patient management in aesthetic
settings.
3. What is the passing score for the CANS exam?
A. 70%
B. 75%
C. 80%
D. 85%
Answer: B
Rationale: The established passing standard for this examination is 75%,
representing the minimum competency level required to practice safely and
effectively in aesthetic nursing.
4. How often must a CANS certification be renewed?
A. Every year
B. Every 2 years
C. Every 3 years
D. Every 5 years
Answer: C
Rationale: A 3-year renewal cycle ensures that certified nurses maintain current
knowledge and skills through ongoing continuing education and practice hours.
2
,5. What is a key consideration when assessing a patient for Botox injections?
A. Blood pressure
B. History of neuromuscular disorders
C. Recent vaccinations
D. Dietary preferences
Answer: B
Rationale: Neurotoxins act at the neuromuscular junction. A history of
neuromuscular disorders (e.g., myasthenia gravis) increases the risk of systemic
effects and severe weakness, making this a critical safety assessment.
6. Which of the following is a contraindication for neurotoxin administration?
A. Mild facial asymmetry
B. Active infection at the injection site
C. History of migraine headaches
D. Previous cosmetic procedures
Answer: B
Rationale: Injecting into an area with active infection can introduce pathogens
deeper into tissues, causing cellulitis or abscess, and compromises healing.
7. How long should a patient wait between facial filler and Botox injections?
A. 1-3 days
B. 7-10 days
C. 14-21 days
D. 30 days
Answer: B
Rationale: Waiting 7-10 days allows dermal fillers to fully integrate and settle
into the tissue. This reduces the risk of distortion or displacement when
subsequent neurotoxin injections are performed in adjacent areas.
8. Which neurotoxin is manufactured by Allergan?
A. Dysport
B. Xeomin
C. Botox
3
, D. Jeuveau
Answer: C
Rationale: Botox (onabotulinumtoxinA) is the original botulinum toxin type A
product and is specifically manufactured by Allergan.
9. Which neurotoxin is manufactured by Medicis?
A. Botox
B. Dysport
C. Xeomin
D. Jeuveau
Answer: B
Rationale: Dysport (abobotulinumtoxinA) is produced by Medicis, distinguishing it
from other neurotoxins with different manufacturing processes and diffusion
profiles.
10. Which neurotoxin is manufactured by Merz?
A. Botox
B. Dysport
C. Xeomin
D. All of the above
Answer: C
Rationale: Xeomin (incobotulinumtoxinA) is the neurotoxin manufactured by
Merz.
It is unique in that it lacks complexing proteins.
11. What is the primary mechanism of action of botulinum toxin type A?
A. Stimulates collagen production
B. Blocks acetylcholine release at the neuromuscular junction
C. Increases blood flow to the area
D. Destroys muscle tissue
Answer: B
Rationale: The toxin cleaves SNARE proteins necessary for synaptic vesicle
fusion, preventing acetylcholine exocytosis. This temporarily paralyzes targeted
4
CORRECT ANSWERS WITH RATIONALES |CERTIFIED AESTHETIC
NURSE SPECIALIST LATEST UPDATE | PSNCB EXAM PREP
GRADED A+
DESCRIPTION
This comprehensive 150-question practice examination is designed for registered
nurses preparing for the Certified Aesthetic Nurse Specialist (CANS) credential
for the 2026/2027 cycle. Aligned with the official test blueprint, this resource
covers all three Clinical Practice Areas: Aesthetic Injectables (55%),
Laser/Light/Energy-Based Therapies (30%), and Clinical Skin Care (15%). Each
item includes the correct answer and a detailed clinical rationale. Topics
include neurotoxins, dermal fillers, sclerotherapy, nonablative and ablative
laser treatments, chemical peels, topical products, patient assessment, informed
consent, complication management, and ethical considerations. Perfect for
self-assessment, study groups, and final exam readiness.
TABLE OF CONTENTS
Section I Aesthetic Injectables – Neurotoxins ........................ 1–25
Section II Aesthetic Injectables – Dermal Fillers ..................... 26–50
Section III Aesthetic Injectables – Sclerotherapy ...................... 51–55
Section IV Laser, Light & Energy-Based Therapies – Nonablative ........ 56–85
Section V Laser, Light & Energy-Based Therapies – Ablative & Other ... 86–100
Section VI Clinical Skin Care – Topical Products & Devices ............ 101–120
Section VII Clinical Skin Care – Chemical Peels & Exfoliation .......... 121–130
Section VIII Patient Assessment, Consultation & Ethics ................. 131–150
SECTION I: AESTHETIC INJECTABLES – NEUROTOXINS (1-25)
1. What is the primary role of a Certified Aesthetic Nurse Specialist (CANS)?
A. Perform surgical procedures independently
B. Provide non-surgical aesthetic treatments and patient care
C. Manage hospital administration
D. Conduct academic research
Answer: B
Rationale: The CANS credential specifically validates expertise in non-surgical
1
,aesthetic interventions. Surgical procedures require physician training, and
administration or research are not the primary clinical focus of this certification.
2. What is the minimum experience required for CANS certification eligibility?
A. 1 year and 500 hours
B. 2 years and 1,000 hours of aesthetic nursing practice
C. 3 years and 1,500 hours
D. No experience required
Answer: B
Rationale: Eligibility requires substantial clinical exposure to ensure the nurse
has developed sufficient judgment and technical skill. The 2-year/1,000-hour
threshold reflects the need for hands-on patient management in aesthetic
settings.
3. What is the passing score for the CANS exam?
A. 70%
B. 75%
C. 80%
D. 85%
Answer: B
Rationale: The established passing standard for this examination is 75%,
representing the minimum competency level required to practice safely and
effectively in aesthetic nursing.
4. How often must a CANS certification be renewed?
A. Every year
B. Every 2 years
C. Every 3 years
D. Every 5 years
Answer: C
Rationale: A 3-year renewal cycle ensures that certified nurses maintain current
knowledge and skills through ongoing continuing education and practice hours.
2
,5. What is a key consideration when assessing a patient for Botox injections?
A. Blood pressure
B. History of neuromuscular disorders
C. Recent vaccinations
D. Dietary preferences
Answer: B
Rationale: Neurotoxins act at the neuromuscular junction. A history of
neuromuscular disorders (e.g., myasthenia gravis) increases the risk of systemic
effects and severe weakness, making this a critical safety assessment.
6. Which of the following is a contraindication for neurotoxin administration?
A. Mild facial asymmetry
B. Active infection at the injection site
C. History of migraine headaches
D. Previous cosmetic procedures
Answer: B
Rationale: Injecting into an area with active infection can introduce pathogens
deeper into tissues, causing cellulitis or abscess, and compromises healing.
7. How long should a patient wait between facial filler and Botox injections?
A. 1-3 days
B. 7-10 days
C. 14-21 days
D. 30 days
Answer: B
Rationale: Waiting 7-10 days allows dermal fillers to fully integrate and settle
into the tissue. This reduces the risk of distortion or displacement when
subsequent neurotoxin injections are performed in adjacent areas.
8. Which neurotoxin is manufactured by Allergan?
A. Dysport
B. Xeomin
C. Botox
3
, D. Jeuveau
Answer: C
Rationale: Botox (onabotulinumtoxinA) is the original botulinum toxin type A
product and is specifically manufactured by Allergan.
9. Which neurotoxin is manufactured by Medicis?
A. Botox
B. Dysport
C. Xeomin
D. Jeuveau
Answer: B
Rationale: Dysport (abobotulinumtoxinA) is produced by Medicis, distinguishing it
from other neurotoxins with different manufacturing processes and diffusion
profiles.
10. Which neurotoxin is manufactured by Merz?
A. Botox
B. Dysport
C. Xeomin
D. All of the above
Answer: C
Rationale: Xeomin (incobotulinumtoxinA) is the neurotoxin manufactured by
Merz.
It is unique in that it lacks complexing proteins.
11. What is the primary mechanism of action of botulinum toxin type A?
A. Stimulates collagen production
B. Blocks acetylcholine release at the neuromuscular junction
C. Increases blood flow to the area
D. Destroys muscle tissue
Answer: B
Rationale: The toxin cleaves SNARE proteins necessary for synaptic vesicle
fusion, preventing acetylcholine exocytosis. This temporarily paralyzes targeted
4
